0.96
-0.0043(-0.45%)
Currency In USD
| Previous Close | 0.97 |
| Open | 0.94 |
| Day High | 0.96 |
| Day Low | 0.91 |
| 52-Week High | 1.69 |
| 52-Week Low | 0.75 |
| Volume | 371,960 |
| Average Volume | 565,525 |
| Market Cap | 35.24M |
| PE | -2.53 |
| EPS | -0.38 |
| Moving Average 50 Days | 1.17 |
| Moving Average 200 Days | 1.15 |
| Change | -0 |
If you invested $1000 in RenovoRx, Inc. (RNXT) since IPO date, it would be worth $132.44 as of November 08, 2025 at a share price of $0.962. Whereas If you bought $1000 worth of RenovoRx, Inc. (RNXT) shares 3 years ago, it would be worth $495.62 as of November 08, 2025 at a share price of $0.962.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD
GlobeNewswire Inc.
Nov 06, 2025 1:30 PM GMT
Company Appoints Distinguished UCLA Oncology Surgeon to SAB, Enhancing Board’s Expertise in Surgical Oncology and Translational Oncology Research Aimed at Improving Multidisciplinary Treatment StrategiesMOUNTAIN VIEW, Calif., Nov. 06, 2025 (GLOBE N
RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th
GlobeNewswire Inc.
Nov 04, 2025 1:30 PM GMT
MOUNTAIN VIEW, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared
RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET
GlobeNewswire Inc.
Oct 27, 2025 12:30 PM GMT
MOUNTAIN VIEW, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared dr